These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 22977012)

  • 1. Detection of PPARδ agonists GW1516 and GW0742 and their metabolites in human urine.
    Sobolevsky T; Dikunets M; Sukhanova I; Virus E; Rodchenkov G
    Drug Test Anal; 2012 Oct; 4(10):754-60. PubMed ID: 22977012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic study of GW1516 in equine urine using liquid chromatography/electrospray ionization Q-Exactive high-resolution mass spectrometry for doping control.
    Ishii H; Shibuya M; Leung GN; Yamashita S; Yamada M; Kushiro A; Kasashima Y; Okada J; Kawasaki K; Kijima-Suda I
    Rapid Commun Mass Spectrom; 2021 Mar; 35(5):e9028. PubMed ID: 33319421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of two major urinary metabolites of the PPARdelta-agonist GW1516 and implementation of the drug in routine doping controls.
    Thevis M; Möller I; Thomas A; Beuck S; Rodchenkov G; Bornatsch W; Geyer H; Schänzer W
    Anal Bioanal Chem; 2010 Apr; 396(7):2479-91. PubMed ID: 19946680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis, mass spectrometric characterization, and analysis of the PPARδ agonist GW1516 and its major human metabolites: targets in sports drug testing.
    Thevis M; Möller I; Beuck S; Schänzer W
    Methods Mol Biol; 2013; 952():301-12. PubMed ID: 23100242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Doping control analysis of GW1516 in equine plasma using liquid chromatography/electrospray ionization Q-Exactive high-resolution mass spectrometry.
    Ishii H; Leung GN; Yamashita S; Yamada M; Kushiro A; Kasashima Y; Okada J; Kawasaki K; Kijima-Suda I
    Rapid Commun Mass Spectrom; 2020 Dec; 34(23):e8920. PubMed ID: 32776613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection and longitudinal distribution of GW1516 and its metabolites in equine hair for doping control using liquid chromatography/high-resolution mass spectrometry.
    Ishii H; Shibuya M; Leung GN; Nozawa S; Yamashita S; Yamada M; Kushiro A; Kasashima Y; Okada J; Kawasaki K; Kijima-Suda I
    Rapid Commun Mass Spectrom; 2021 Apr; 35(8):e9050. PubMed ID: 33470485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peroxisome proliferator-activated receptor δ agonist GW1516 attenuates diet-induced aortic inflammation, insulin resistance, and atherosclerosis in low-density lipoprotein receptor knockout mice.
    Bojic LA; Burke AC; Chhoker SS; Telford DE; Sutherland BG; Edwards JY; Sawyez CG; Tirona RG; Yin H; Pickering JG; Huff MW
    Arterioscler Thromb Vasc Biol; 2014 Jan; 34(1):52-60. PubMed ID: 24158519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural insights into human peroxisome proliferator activated receptor delta (PPAR-delta) selective ligand binding.
    Batista FA; Trivella DB; Bernardes A; Gratieri J; Oliveira PS; Figueira AC; Webb P; Polikarpov I
    PLoS One; 2012; 7(5):e33643. PubMed ID: 22606221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective effects of a peroxisome proliferator-activated receptor-beta/delta agonist in experimental autoimmune encephalomyelitis.
    Polak PE; Kalinin S; Dello Russo C; Gavrilyuk V; Sharp A; Peters JM; Richardson J; Willson TM; Weinberg G; Feinstein DL
    J Neuroimmunol; 2005 Nov; 168(1-2):65-75. PubMed ID: 16098614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parallel Chemistry Approach to Identify Novel Nuclear Receptor Ligands Based on the GW0742 Scaffold.
    Teske KA; Rai G; Nandhikonda P; Sidhu PS; Feleke B; Simeonov A; Yasgar A; Jadhav A; Maloney DJ; Arnold LA
    ACS Comb Sci; 2017 Oct; 19(10):646-656. PubMed ID: 28825467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Both the peroxisome proliferator-activated receptor delta agonist, GW0742, and ezetimibe promote reverse cholesterol transport in mice by reducing intestinal reabsorption of HDL-derived cholesterol.
    Briand F; Naik SU; Fuki I; Millar JS; Macphee C; Walker M; Billheimer J; Rothblat G; Rader DJ
    Clin Transl Sci; 2009 Apr; 2(2):127-33. PubMed ID: 20169010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The PPARδ agonist GW0742 restores neuroimmune function by regulating Tim-3 and Th17/Treg-related signaling in the BTBR autistic mouse model.
    Ahmad SF; Nadeem A; Ansari MA; Bakheet SA; Alshammari MA; Attia SM
    Neurochem Int; 2018 Nov; 120():251-261. PubMed ID: 30227151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive characterization of the peroxisome proliferator activated receptor-δ agonist GW501516 for horse doping control analysis.
    Trevisiol S; Moulard Y; Delcourt V; Jaubert M; Boyer S; Tendon S; Haryouli H; Taleb W; Caroff M; Chabot B; Drif L; André F; Garcia P; Loup B; Popot MA; Bailly-Chouriberry L
    Drug Test Anal; 2021 Jun; 13(6):1191-1202. PubMed ID: 33547737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans.
    Prakash C; Kamel A; Gummerus J; Wilner K
    Drug Metab Dispos; 1997 Jul; 25(7):863-72. PubMed ID: 9224781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiac peroxisome proliferator-activated receptor δ (PPARδ) as a new target for increased contractility without altering heart rate.
    Chen ZC; Lee KS; Chen LJ; Wang LY; Niu HS; Cheng JT
    PLoS One; 2013; 8(5):e64229. PubMed ID: 23724037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simultaneous determination of MK-0767 and seven metabolites in rat urine using liquid chromatography/tandem mass spectrometry.
    Shen Z; Kochansky C; Bakhtiar R; Franklin RB; Vincent SH
    Rapid Commun Mass Spectrom; 2004; 18(18):2113-20. PubMed ID: 15317046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peroxisome proliferator-activated receptor δ agonist attenuates hepatic steatosis by anti-inflammatory mechanism.
    Lee MY; Choi R; Kim HM; Cho EJ; Kim BH; Choi YS; Naowaboot J; Lee EY; Yang YC; Shin JY; Shin YG; Chung CH
    Exp Mol Med; 2012 Oct; 44(10):578-85. PubMed ID: 22824914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GW0742 activates peroxisome proliferator-activated receptor δ to reduce free radicals and alleviate cardiac hypertrophy induced by hyperglycemia in cultured H9c2 cells.
    Cheng KC; Chang WT; Li Y; Cheng YZ; Cheng JT; Chen ZC
    J Cell Biochem; 2018 Nov; 119(11):9532-9542. PubMed ID: 30129179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PPARδ activation protects endothelial function in diabetic mice.
    Tian XY; Wong WT; Wang N; Lu Y; Cheang WS; Liu J; Liu L; Liu Y; Lee SS; Chen ZY; Cooke JP; Yao X; Huang Y
    Diabetes; 2012 Dec; 61(12):3285-93. PubMed ID: 22933110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and Evaluation of PPARδ Agonists That Promote Osteogenesis in a Human Mesenchymal Stem Cell Culture and in a Mouse Model of Human Osteoporosis.
    Kress BJ; Kim DH; Mayo JR; Farris JT; Heck B; Sarver JG; Andy D; Trendel JA; Heck BE; Erhardt PW
    J Med Chem; 2021 May; 64(10):6996-7032. PubMed ID: 33988379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.